EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lead Optimization of the 5-Phenylpyrazolopyrimidinone NPD-2975 toward Compounds with Improved Antitrypanosomal Efficacy

Yang Zheng iD, Magali van den Kerkhof, Mohamed Ibrahim, Iwan J P De Esch iD, Louis Maes, Geert Jan Sterk, Guy Caljon, Rob Leurs iD

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.3c01976 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Yang Zheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam Institute of Molecular and Life Sciences, Division of Medicinal Chemistry, Faculty of Science, Vrije Universiteit Amsterdam, De Boelelaan 1…. Hauptthemen laut MEDLINE: Trypanocidal Agents, Trypanosomiasis, African, Antiprotozoal Agents, Trypanosoma brucei brucei. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FP7 Health, China Scholarship Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human African trypanosomiasis (HAT) still faces few therapeutic options and emerging drug resistance, stressing an urgency for novel antitrypanosomal drug discovery. Here, we describe lead optimization efforts aiming at improving antitrypanosomal efficacy and better physicochemical properties based on our previously reported optimized hit NPD-2975 (pIC50 7.2). Systematic modification of the 5-phenylpyrazolopyrimidinone NPD-2975 led to the discovery of a R4-substituted analogue 31c (NPD-3519), showing higher in vitro potency (pIC50 7.8) against Trypanosoma brucei and significantly better metabolic stability. Further, in vivo pharmacokinetic evaluation of 31c and experiments in an acute T. brucei mouse model confirmed improved oral bioavailability and antitrypanosomal efficacy at 50 mg/kg with no apparent toxicity. With good physicochemical properties, low toxicity, improved pharmacokinetic features, and in vivo efficacy, 31c may serve as a promising candidate for future drug development for HAT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Trypanocidal AgentsTrypanosomiasis, AfricanAntiprotozoal AgentsTrypanosoma brucei bruceiAnimalsMiceHumansDrug Development

Substanzen

Trypanocidal AgentsAntiprotozoal Agents

Autor:innen und Institutionen

  • Amsterdam Institute of Molecular and Life Sciences, Division of Medicinal Chemistry, Faculty of Science, Vrije Universiteit Amsterdam, De Boelelaan 1108, Amsterdam 1081 HZ, The Netherlands.
  • Laboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, Wilrijk 2610, Belgium.

ORCID-Profile: Yang Zheng, Iwan J P De Esch, Rob Leurs

Förderung

  • FP7 Health
  • China Scholarship Council

Zitieren

APA

Zheng, Y., van den Kerkhof, M., Ibrahim, M., De Esch, I. J. P., Maes, L., Sterk, G. J., Caljon, G., & Leurs, R. (2024). Lead Optimization of the 5-Phenylpyrazolopyrimidinone NPD-2975 toward Compounds with Improved Antitrypanosomal Efficacy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01976

Vancouver

Zheng Y, van den Kerkhof M, Ibrahim M, De Esch IJP, Maes L, Sterk GJ, et al. Lead Optimization of the 5-Phenylpyrazolopyrimidinone NPD-2975 toward Compounds with Improved Antitrypanosomal Efficacy. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c01976

BibTeX
@article{Zheng2024,
  author = {Zheng, Yang and van den Kerkhof, Magali and Ibrahim, Mohamed and De Esch, Iwan J P and Maes, Louis and Sterk, Geert Jan and Caljon, Guy and Leurs, Rob},
  title = {Lead Optimization of the 5-Phenylpyrazolopyrimidinone NPD-2975 toward Compounds with Improved Antitrypanosomal Efficacy},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.3c01976}
}
Kostenlos starten →